There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Tobias Guennel |
| Institution: | Precision for Medicine |
| Department: | Translational Informatics |
| Country: | |
| Proposed Analysis: | Alzheimer’s Disease (AD) is a complex disease and a significant amount of research has be done to evaluate the impact of biomarkers in CSF and plasma on disease progression indicator. The goal of this research is to evaluate the subpopulations in MCI according to biomarker data in CSF and plasma and clinical factors and to assess the relationship between profiles of the subpopulations and socioeconomic outcomes in the US. This is a retrospective cohort study to evaluate risk signatures for cognitive decline and MCI in the ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) data. Several characteristics will be evaluated in the risk algorithm including predicted biomarkers derived using machine learning techniques, survey instruments, and demographic factors. Classification of risk will be based on the likelihood of cognitive decline and / or phenotypic conversion from normal cognition to MCI within a 5-year time frame. Precision will use simulations on the subpopulations to project individual economic and any applicable available health outcomes over time to understand the the general characteristics of biomarker levels in AD and uncover differences between normal controls as well as MCI and AD patients that are driven by CSF and plasma biomarker levels. |
| Additional Investigators |
